Literature DB >> 25146349

Danhong enhances recovery from residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo.

Wenting Deng1, Chuanhong Yang2, Min Xiong3, Xiaoyan Fu1, Huangwen Lai2, Weiyi Huang4.   

Abstract

OBJECTIVES: Although the repositioning maneuvers are usually very effective in patients with BPPV, some patients still complain residual dizziness. Danhong injection (DHI), a traditional Chinese medicine, can effectively dilate blood vessels and improve microcirculation, and has been proven to be effective in improving cervical vertigo and posterior circulation ischemic vertigo. The aim of this study was to evaluate the effects of DHI on residual dizziness after successful repositioning treatment in patients with BPPV.
METHODS: Eighty-six patients with BPPV were randomized into two treatment groups, DHI group and non DHI group. The DHI group received the same repositioning treatment as the non-DHI group, with the addition of DHI therapy. The durations of residual dizziness of DHI group and non-DHI group were compared. In addition, the scores of the dizziness handicap inventory of these two groups were calculated.
RESULTS: The durations of residual dizziness of DHI group were shorter than that of non-DHI group. There were no significant differences in the scores of dizziness handicap inventory in the first week between these two groups, and there were much significant differences in the second, the fourth, the sixth and eighth weeks.
CONCLUSIONS: The results demonstrate that DHI can significantly improve the residual dizziness after successful repositioning treatment in patients with BPPV.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25146349     DOI: 10.1016/j.amjoto.2014.07.001

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  7 in total

1.  Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial.

Authors:  Peng Qian Wang; Dan Dan Li; Wei Dong; Jun Liu; Ya Nan Yu; Chun Ti Shen; Qi Guang Chen; Bing Wei Chen; Yun Dai Chen; Zhong Wang
Journal:  Trials       Date:  2015-10-21       Impact factor: 2.279

Review 2.  Residual Dizziness after Successful Repositioning Maneuver for Idiopathic Benign Paroxysmal Positional Vertigo: A Review.

Authors:  Giorgia Giommetti; Ruggero Lapenna; Roberto Panichi; Puya Dehgani Mobaraki; Fabrizio Longari; Giampietro Ricci; Mario Faralli
Journal:  Audiol Res       Date:  2017-05-09

3.  Efficacy of betahistine plus cognitive behavioral therapy on residual dizziness after successful canalith repositioning procedure for benign paroxysmal positional vertigo.

Authors:  Tian-Ju Wan; Yi-Chuan Yu; Xiao-Gang Zhao; Ping Tang; Yong-Shu Gong
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-05       Impact factor: 2.570

4.  Linggui Zhugan Decoction for peripheral vertigo: A protocol for systematic review and meta-analysis.

Authors:  Hongmei Ma; Liang Guo; Yong Chen; Wanning Lan; Jiyuan Zheng; Danyun Li; Ziyin Chen; Xinju Hou
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

5.  Betahistine alleviates benign paroxysmal positional vertigo (BPPV) through inducing production of multiple CTRP family members and activating the ERK1/2-AKT/PPARy pathway.

Authors:  Jing Hui; Qi Lei; Zhi Ji; Dingjing Zi
Journal:  Biol Res       Date:  2022-04-04       Impact factor: 5.612

6.  Elevated red cell distribution width predicts residual dizziness in patients with benign paroxysmal positional vertigo.

Authors:  Ke-Hang Xie; Li-Chun Chen; Ling-Ling Liu; Chu-Yin Su; Hua Li; Run-Ni Liu; Qing-Qing Chen; Jia-Sheng He; Yong-Kun Ruan; Wang-Kai He
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

7.  Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial.

Authors:  Bing Li; Yilong Wang; Jingjing Lu; Jun Liu; Ye Yuan; Yanan Yu; Pengqian Wang; Xingquan Zhao; Zhong Wang
Journal:  Trials       Date:  2015-12-09       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.